Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies

References

• Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220 - 41; http://dx.doi.org/10.3322/caac.21149; PMID: 22700443
   PubMed Web of Science ®Google Scholar
• Bhatia S. Long-term complications of therapeutic exposures in childhood: lessons learned from childhood cancer survivors. Pediatrics 2012; 130:1141 - 3; http://dx.doi.org/10.1542/peds.2012-2884; PMID: 23166341
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, et al, Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572 - 82; http://dx.doi.org/10.1056/NEJMsa060185; PMID: 17035650
   PubMed Web of Science ®Google Scholar
• Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252:9 - 18; http://dx.doi.org/10.1016/j.canlet.2006.11.005; PMID: 17166655
   PubMed Web of Science ®Google Scholar
• Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 1982; 7:147 - 50; http://dx.doi.org/10.1007/BF00254537; PMID: 7083455
   PubMed Web of Science ®Google Scholar
• Lowis SP, Pearson AD, Newell DR, Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 1993; 53:4881 - 9; PMID: 8402676
   PubMed Web of Science ®Google Scholar
• Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 2012; 9:2444 - 53; http://dx.doi.org/10.3390/ijerph9072444; PMID: 22851953
   PubMed Web of Science ®Google Scholar
• McLeod HL, Evans WE. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv 1993; 17:253 - 68; PMID: 8137343
   PubMedGoogle Scholar
• Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12:2390 - 7; PMID: 7964955
   PubMed Web of Science ®Google Scholar
• Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994; 34:Suppl S69 - 75; http://dx.doi.org/10.1007/BF00684867; PMID: 8070031
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014; 66C:2 - 25; http://dx.doi.org/10.1016/j.addr.2013.11.009; PMID: 24270007
   PubMed Web of Science ®Google Scholar
• Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011; 44:979 - 89; http://dx.doi.org/10.1021/ar200077p; PMID: 21902173
   PubMed Web of Science ®Google Scholar
• Paolino D, Licciardi M, Celia C, Giammona G, Fresta M, Cavallaro G. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model. Eur J Pharm Biopharm 2012; 82:94 - 102; http://dx.doi.org/10.1016/j.ejpb.2012.06.001; PMID: 22705641
   PubMed Web of Science ®Google Scholar
• Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat Nanotechnol 2008; 3:242 - 4; http://dx.doi.org/10.1038/nnano.2008.114; PMID: 18654511
   PubMed Web of Science ®Google Scholar
• Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 2011; 44:1094 - 104; http://dx.doi.org/10.1021/ar200105p; PMID: 21812415
   PubMed Web of Science ®Google Scholar
• Hwang SY, Cho Y, Kim HK, Cho SH, Choo J, Yoon WJ, Lee EK. Preparation of targeting proteoliposome by postinsertion of a linker molecule conjugated with recombinant human epidermal growth factor. Bioconjug Chem 2010; 21:345 - 51; http://dx.doi.org/10.1021/bc9004409; PMID: 20078100
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160:117 - 34; http://dx.doi.org/10.1016/j.jconrel.2012.03.020; PMID: 22484195
   PubMed Web of Science ®Google Scholar
• Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, Jacobs A, Curtin J, Muggia F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18:716 - 21; http://dx.doi.org/10.1093/annonc/mdl484; PMID: 17301073
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011; 43:174 - 9; http://dx.doi.org/10.1016/j.ejps.2011.04.005; PMID: 21530654
   PubMed Web of Science ®Google Scholar
• Sengupta S, Tyagi P, Velpandian T, Gupta YK, Gupta SK. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 2000; 42:459 - 64; http://dx.doi.org/10.1006/phrs.2000.0714; PMID: 11023708
   PubMed Web of Science ®Google Scholar
• Wu W, Huang J, Liu S, Li X, Cai Y. [Study on pharmacokinetics and tissue distribution of stealth matrine liposomes in rats]. Zhongguo Zhong Yao Za Zhi 2009; 34:751 - 5; PMID: 19624022
   PubMedGoogle Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, Sawant KK, Murthy RS. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 2011; 150:2 - 22; http://dx.doi.org/10.1016/j.jconrel.2010.11.002; PMID: 21095210
   PubMed Web of Science ®Google Scholar
• Wong JY, Kuhl TL, Israelachvili JN, Mullah N, Zalipsky S. Direct measurement of a tethered ligand-receptor interaction potential. Science 1997; 275:820 - 2; http://dx.doi.org/10.1126/science.275.5301.820; PMID: 9012346
   PubMed Web of Science ®Google Scholar
• Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1995; 1234:74 - 80; http://dx.doi.org/10.1016/0005-2736(94)00263-O; PMID: 7880861
   PubMed Web of Science ®Google Scholar
• Posse de Chaves E, Sipione S. Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett 2010; 584:1748 - 59; http://dx.doi.org/10.1016/j.febslet.2009.12.010; PMID: 20006608
   PubMed Web of Science ®Google Scholar
• Pagnan G, Montaldo PG, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 1999; 81:268 - 74; http://dx.doi.org/10.1002/(SICI)1097-0215(19990412)81:2<268::AID-IJC17>3.0.CO;2-1; PMID: 10188730
   PubMed Web of Science ®Google Scholar
• Wiegandt H. The chemical constitution of gangliosides of the vertebrate nervous system. Behav Brain Res 1995; 66:85 - 97; http://dx.doi.org/10.1016/0166-4328(94)00129-4; PMID: 7755905
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al, Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324 - 34; http://dx.doi.org/10.1056/NEJMoa0911123; PMID: 20879881
   PubMed Web of Science ®Google Scholar
• Czaplicki D, Horwacik I, Kowalczyk A, Wieczorek A, Bolek-Marzec K, Balwierz W, Kozik A, Rokita H. New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients. Acta Biochim Pol 2009; 56:423 - 31; PMID: 19724779
   PubMed Web of Science ®Google Scholar
• Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985; 45:2642 - 9; PMID: 2580625
   PubMed Web of Science ®Google Scholar
• Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013; 13:397 - 411; http://dx.doi.org/10.1038/nrc3526; PMID: 23702928
   PubMed Web of Science ®Google Scholar
• Munn DH, Cheung NK. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987; 47:6600 - 5; PMID: 3499978
   PubMed Web of Science ®Google Scholar
• Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer 2007; 48:430 - 4; http://dx.doi.org/10.1002/pbc.20765; PMID: 16421906
   PubMed Web of Science ®Google Scholar
• Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 2010; 145:66 - 73; http://dx.doi.org/10.1016/j.jconrel.2010.03.015; PMID: 20346382
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Loi M, Di Paolo D, Di Fiore A, Perri P, Pagnan G, Ponzoni M. Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma. Front Oncol 2013; 3:190; http://dx.doi.org/10.3389/fonc.2013.00190; PMID: 23936762
   PubMedGoogle Scholar
• Brignole C, Pastorino F, Marimpietri D, Pagnan G, Pistorio A, Allen TM, Pistoia V, Ponzoni M. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst 2004; 96:1171 - 80; http://dx.doi.org/10.1093/jnci/djh221; PMID: 15292389
   PubMed Web of Science ®Google Scholar
• Gentine P, Bourel-Bonnet L, Frisch B. Modified and derived ethanol injection toward liposomes: development of the process. J Liposome Res 2013; 23:11 - 9; http://dx.doi.org/10.3109/08982104.2012.717298; PMID: 23020802
   PubMed Web of Science ®Google Scholar
• Ali-Rahmani F, Hengst JA, Connor JR, Schengrund CL. Effect of HFE variants on sphingolipid expression by SH-SY5Y human neuroblastoma cells. Neurochem Res 2011; 36:1687 - 96; http://dx.doi.org/10.1007/s11064-011-0403-8; PMID: 21243428
   PubMed Web of Science ®Google Scholar
• Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, et al. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther 2011; 19:2201 - 12; http://dx.doi.org/10.1038/mt.2011.142; PMID: 21829174
   PubMed Web of Science ®Google Scholar
• Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 2006; 10:839 - 50; http://dx.doi.org/10.1016/j.devcel.2006.04.002; PMID: 16740485
   PubMed Web of Science ®Google Scholar
• Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, Prenter S, Harvey H, Domingo-Fernández R, Bray IM, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 2012; 7:e38129; http://dx.doi.org/10.1371/journal.pone.0038129; PMID: 22662276
   PubMed Web of Science ®Google Scholar
• Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985; 812:55 - 65; http://dx.doi.org/10.1016/0005-2736(85)90521-8; PMID: 23008845
   PubMed Web of Science ®Google Scholar
• Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003; 105:561 - 7; http://dx.doi.org/10.1002/ijc.11108; PMID: 12712451
   PubMed Web of Science ®Google Scholar
• Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994; 1190:99 - 107; http://dx.doi.org/10.1016/0005-2736(94)90038-8; PMID: 8110825
   PubMed Web of Science ®Google Scholar
• Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1992; 1104:95 - 101; http://dx.doi.org/10.1016/0005-2736(92)90136-A; PMID: 1550858
   PubMed Web of Science ®Google Scholar
• Chang WK, Tai YJ, Chiang CH, Hu CS, Hong PD, Yeh MK. The comparison of protein-entrapped liposomes and lipoparticles: preparation, characterization, and efficacy of cellular uptake. Int J Nanomedicine 2011; 6:2403 - 17; PMID: 22072876
   PubMed Web of Science ®Google Scholar
• Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999; 122:449 - 60; http://dx.doi.org/10.1093/brain/122.3.449; PMID: 10094254
   PubMed Web of Science ®Google Scholar
• Yu RK, Tsai YT, Ariga T. Functional roles of gangliosides in neurodevelopment: an overview of recent advances. Neurochem Res 2012; 37:1230 - 44; http://dx.doi.org/10.1007/s11064-012-0744-y; PMID: 22410735
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M. Doxorubicin-loaded Fab’ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003; 63:86 - 92; PMID: 12517782
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012; 1:477 - 86; http://dx.doi.org/10.4161/onci.19864; PMID: 22754766
   PubMed Web of Science ®Google Scholar
• Licciardi M, Paolino D, Celia C, Giammona G, Cavallaro G, Fresta M. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials 2010; 31:7340 - 54; http://dx.doi.org/10.1016/j.biomaterials.2010.05.060; PMID: 20609469
   PubMed Web of Science ®Google Scholar